engleski

Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery

We read with interest the article by Forcillo and colleagues1 on intramyocardial CD133+ autologous bone marrow stem cell application during coronary artery bypass grafting in patients with ischemic cardiomyopathy. This open-label pilot study of only 5 patients assessed safety and feasibility of the procedure. No increase in global ejection fraction was noted, but stress echocardiography and magnetic resonance imaging revealed improved regional contractility and morphology in the injected myocardium.

stem cells ; coronary bypass surgery

nije evidentirano